Clinical Trials Search
Clinical Trial 17790
Interventions:Alkeran (Melphalan); CC-5013 (Lenalidomide); Lenalidomide (Revlimid); Marrow Infiltrating Lymphocytes (MILs); Melphalan; Tadalafil
Study Type: Treatment
Phase of Study: Phase II
- Frederick Locke
A Randomized Phase II Study of Autologous Stem Cell Transplantation with Tadalafil and Lenalidomide Maintenance with or without Activated Marrow Infiltrating Lymphocytes (MILs) in High Risk Myeloma
The purpose of this study is to find out if altering the immune system by giving Tadalafil, and activated marrow-infiltrating lymphocytes (aMILs) can improve outcomes for multiple myeloma patients who receive a standard autologous stem cell transplant.
Primary: Determine the progression free survival (PFS) of autologous stem cell transplant (ASCT) alone vs ASCT plus MILs. Secondary: Evaluate Toxicity; Evaluate Overall Survival; Determine Immune Responses; Anti-Tumor Immune Responses.